Research Labs

The Mara Sherman lab aims to understand the heterocellular interactions among pancreatic cancer cells and their surrounding microenvironment, and to target these networks for therapeutic benefit.

Physician-scientist Samuel Singer studies the genomic alterations that define new targets for therapy in sarcoma. I am a surgical oncologist who specializes in the diagnosis and treatment of soft tissue sarcoma. I have extensive experience with this group of cancers, and am one of just a few surgeons in the world focused solely on treating sarcoma patients. My years of experience have enabled me to devise surgical techniques that improve the ability to completely remove these tumors. In addition to my clinical sarcoma practice, I conduct laboratory research to develop new methods to improve the diagnosis and treatment of sarcoma. I lead both a National Cancer Institute Specialized Program in Research Excellence (SPORE) and the Sarcoma Genome Project.

Physician-scientist David Solit studies human oncology and pathogenesis, genomics, oncogenes and tumor suppressors, cancer therapeutics, and clinical trials.

Physician-scientist Viviane Tabar focuses on stem cells as tools for brain repair and for modeling brain cancer.

Physician-scientist Laura Tang studies the molecular pathogenesis of cell transformation in neuroendocrine neoplasms of the gastrointestinal tract and pancreas and adenocarcinomas of the stomach and gastrointestinal junction.

The Taylor laboratory studies the influence of the nervous system on pediatric and young adult cancers.

The Tulpule lab studies how cells compartmentalize critical cellular processes with a focus on biomolecular condensates in cancer.

The laboratory investigates cellular lipid and energy metabolism, in particular the mechanisms and physiology of neutral lipid synthesis and storage in lipid droplets.

Physician-scientist Martin Weiser investigates the mechanisms underlying tumor spread and metastasis and how these mechanisms could be targeted.

Cancer biologist Hans-Guido Wendel pursues both disease-centered and basic discovery research. The disease focus is on lymphocyte malignancies and the basic science arm of the lab explores fundamental mechanisms that control aberrant mRNA translation programs in cancer. Work in these two research areas frequently intersects in surprising ways.